News Article | March 2, 2017
BARCELONA, Spain, March 2, 2017 /PRNewswire/ -- Leading smartphone manufacturer Vivo presented its technological development in High Power User Equipment (HPUE) at the Global TD-LTE Initiative (GTI) Summit 2017 on Feb. 23 in Barcelona, showcasing its commitment to heralding in the...
News Article | March 2, 2017
BARCELONA, Spain, Mar. 2, 2017 /PRNewswire/ -- Leading smartphone manufacturer Vivo presented its technological development in High Power User Equipment (HPUE) at the Global TD-LTE Initiative (GTI) Summit 2017 on Feb. 23 in Barcelona, showcasing its commitment to heralding in the upcoming 5G era. GTI Summit 2017, under the theme "Joint Innovation Towards 5G", brought together the most influential decision makers, policy makers and influencers in the telecommunication industry (including CM, Sprint, MTK etc) to promote TD-LTE global development. Vivo, as one of the revolutionaries in this field, demonstrated its newest technological breakthrough in doubling transmission power to help improve user experience when surfing the Internet under weak signals. The technology utilizes high power amplifiers in handset devices to enhance uplink coverage capabilities and stretch 2.5 GHz coverage, offering faster speed and better capacity than the primary band of current telecommunication networks, and thus significantly increases uplink data speed and MOS (Mean Opinion Score) field effect in its products (as tested in a test environment) while internet coverage is limited. The solution takes a progressive step closer to the synergistic 5G ecosystem which will lead to higher speed, larger storage, and faster data processing speed and Vivo is currently working on commercializing this technique and is expected to apply it to the company's new products in the near future. "Vivo has set up its 5G Research Institute in Beijing," said Alex Feng, CMO of Vivo. "Together with our R&D centers in Shenzhen, Dongguan, Nanjing, Hangzhou, Beijing, Silicon Valley, and San Diego, and our accumulated experience in innovating in telecommunications, we have set up a solid foundation for Vivo in the next round of the technical revolution in the 5G era to deliver premium technical innovations in all aspects to our users." A young global smartphone brand focusing on introducing perfect sound quality and ultimate photography with cutting-edge technology, Vivo develops dynamic and stylish products for passionate young people. The company ranks among the top 5 smartphone brands worldwide according to IDC's Q4 2016 report. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vivo-releases-high-power-user-equipment-technology-breakthrough-at-gti-summit-2017-to-herald-5g-300416846.html
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 739.07K | Year: 2012
DESCRIPTION (provided by applicant): The overall objective of this SBIR proposal is to develop and commercialize a human 3D or mini- liver bioassay system suitable for real-time analysis of metabolic functions and long-term drug toxicity profiles. At present, liver functions are mostly studied using HepG2 cell line and primary hepatocytes cultured onto collagen or polymer matrices. However, these 2D monolayer models allow only partial or short-term toxicity analysis due to rapid loss of metabolic functions.Interestingly, spheroid formation in 3D matrix/scaffold cultures is shown to improve host cell functions. In Phase I studies, we successfully demonstrated the feasibility of a new human bioscaffold- 3D HuBiogel (high-density gel) for supporting long-termsurvival and maintenance of primary liver cells. Moreover, integration of rotary bioreactor system allowed efficient production/analysis of viable mini-liver spheroids. We now propose to complete the development of new 3D-liver bioassay platform that exhibits improved metabolic functions, and thus will enable precise drug toxicity testing in vitro. Phase II specific goals are: 1. Establish an efficient hepatic cells cultivation protocol by optimizing 3D HuBiogel scaffolds and rotary bioreactor or perfusionculture strategies; 2. Test functionality of 3D-liver culture model by evaluating key biochemical and metabolism endpoints; and 3. Validate the practical utility of mini-liver assay system via real- time analysis of CYP450 induction and chemical/drug toxicity responses. Comparative control studies will include 3D culture scaffolds of Type-I collagen or Matrigel as well as fresh human liver-slice cultures. High throughput adaptability of 3D-liver bioassay will also be examined for toxicogenomics via CYP-microarrays. Thus, biologic relevance of new marketable 3D-liver bioassay system will be confirmed for improved drug toxicity analysis/prediction in humans. We are confident this advanced in vitro hepatotoxicity model will positively impact basic, preclinicaland biomedical research arenas. Commercial Importance and Significance: No acceptable commercial liver toxicity assay currently exists which utilizes a human bio-scaffold culture system. VBI will develop a market-ready 3D-liver assay platform adaptable toHTS applications. Sale of 3D HuBiogel culture kits or in-house bioassay services would have significant world-wide market, as a research and diagnostic tool. PUBLIC HEALTH RELEVANCE: Current cell-based assay models for studying drug metabolism and toxicity are of limited utility because isolated liver cells die rapidly in their no-physiologic, 2-dimensional (2D) culture formats. In Phase I, we have shown that a novel human 3-dimensional (3D or high- density) biomatrix scaffold- HuBiogel supportslong-term cultivation, survival and functions of primary human liver cells. In Phase II, we will complete the development of new mini-liver bioassay platform by employing 3D HuBiogel scaffolds combined with rotary or perfusion culture techniques. High throughput utility of this robust 3D hepatotoxicity assay will greatly advance biochemical, metabolic and molecular analysis beyond 2D culture methods. Thus, our RandD effort provides a much needed in vitro tool for real-time analysis of chemical/drug metabolism and liver toxicity responses in humans. A successful outcome will offer new market-ready bioassay kits and services with world-wide demand in both basic and pharmaceutical research areas.
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase I | Award Amount: 192.31K | Year: 2014
DESCRIPTION (provided by applicant): In this Phase I STTR proposal, our RandD goal is the development and evaluation of a novel functionally-graded biohybrid vascular graft for small diameter (lt6 mm) coronary bypass applications. Tissue engineered vascular constructs developed to date have mostly utilized synthetic and animal- derived biomaterials and require pre-seeding of host cells before implantation to overcome the complications of prosthetic vascular grafts. However, these graft systems exhibit manylimitations including poor cellular adhesion, inadequate biomechanical and functional properties. The PI has recently demonstrated an in vitro regenerated human endothelium on functionally-layered polymeric scaffolds containing bioactive proteins. Moreover, VBI has developed a unique human biomatrix (HuBiogel) that allows viable tissue constructs by cultivating single or multiple cell types. HuBiogel milieu can also be controlled via enrichment with specific growth factors (VEGF). We now propose to combin
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 279.41K | Year: 2013
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 219.81K | Year: 2015
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 1.97M | Year: 2015
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 156.98K | Year: 2014
DESCRIPTION (provided by applicant): This SBIR project is focused to develop, validate and commercialize an advanced high-throughput anti- tumor drug screening platform (HTS) which employs a new 3D HuBioGEM assay technology. Preclinical drug screening is commonly performed using biochemical and cell-based assay systems. In recent years, more relevant 3D spheroid models have been developed using microcarrier, pHEMA- coating, gel-layer and hanging-drop techniques. Although useful, these require difficult culture protocols, provide undesirable endpoints and/or are not efficient for automated applications. We have created a novel HuBioGEM culture system by formulating patented HuBiogel (human biomatrix) with unique paramagnetic particles (GEM). Employing 3D magnetic-biogel and 384-array culture strategies, we propose to develop a robust human microtumor assay platform for drug efficacy profiling. Phase I technical goals are: i) Establish 3D tumor production, culture and analysis protocols using HuBioGEM, NCI
Vivo Inc | Date: 2015-02-10
Systems and methods estimate expected loss risk to computers and enterprises based on the data files present on computers and data file clusters within the enterprise.
News Article | February 20, 2017
CALGARY, AB--(Marketwired - February 20, 2017) - Join Vivo and MLA Jamie Kleinsteuber for a free FAMILY DAY SKATE from 12pm - 4pm. Whether you are new to skating or a veteran, this favourite Canadian pastime is a great way to get the whole family moving, together. Cross more than just skating off the Participaction #150PlayList -- join our Play Ambassadors for 4-Square, Obstacle Course, Tug of War and our cardboard scooter version of kayaking! "Each February, we take a day to spend some quality time with those closest to us. Whether it's the family we are born with, or the family we create for ourselves, these bonds are an important foundation in our lives!" enthuses MLA Jamie Kleinsteuber. Take a break from play and head to the piazza for our local talent showcase and art auction! Meet and talk with several local artists and bid on the donated, local works of art! Stop by the photo booth to have your photo taken and share your Canada Story! Canada's beauty is in its diversity. This year we are gathering and sharing stories about Canada -- what does Canada mean to you? What makes you proud to be Canadian? What is your favourite memory of Canada? Everyone seems to have a different answer or reason to love this beautiful country -- share your story with us on Family Day! "Sharing our stories deepens our sense of belonging -- and I am happy to work with Vivo to be a part of helping people feel like they belong!" shares Cynthia Watson, Vivo CEO. Join in and share your story -- submit your story via email (email@example.com), on social media tag @VivoYouLife #vivo150 or in person at our Family Day Fun Event! Participaction created the 150 Play List with over 465,000 votes from people across Canada. Including 150 physical activities that make us uniquely Canadian, the Play List is a challenge to Canadians in communities, schools, workplaces, and even abroad to see how many different activities they can complete in 2017. Vivo is on a mission to raise healthier generations in Calgary, and beyond. We're a self-sustaining charity committed to pioneering solutions to get all Canadians moving more, sitting less and connecting with their communities. Our roots are in north-central Calgary where we operate a leading regional recreation centre.